Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NDT/GFL293PMID 16766543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic kidney disease: the global challenge

  2005cited by this paper
• Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

  2005cited by this paper
• Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program

  2004cited by this paper
• Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Angiotensin receptor blockers and myocardial infarction

  2004cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Candesartan reduces oxidative stress and inflammation in patients with essential hypertension.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Cardiovascular Mortality in End-Stage Renal Disease

  2003cited by this paper
• Oxidative stress in heart failure. More than just damage.

  2003cited by this paper
• Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences.

  2003cited by this paper
• Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.

  2003cited by this paper
• Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling.

  2003cited by this paper
• Increased Circulating Levels of Natriuretic Peptides Predict Future Cardiac Event in Patients with Chronic Hemodialysis

  2002cited by this paper
• ACE inhibitors and survival of hemodialysis patients.

  2002cited by this paper
• Vascular inflammation and the renin-angiotensin system.

  2002cited by this paper
• Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease.

  2002cited by this paper
• Arterial hypertension and left ventricular hypertrophy in hemodialysis patients.

  2002cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect.

  2000cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Mechanism of protective effects of ACE inhibition on coronary artery disease.

  1998cited by this paper
• Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects.

  1997cited by this paper
• Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure

  1994cited by this paper
• Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method

  1977cited by this paper
• Matrix metalloproteinase;

  year unknowncited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Hypertension in Patients With End-Stage Kidney Disease Requiring Dialysis: Bridging the Divide Between Evidence and Practice.

  2026cites this paper
• Association between ACEI/ARB and short-term prognosis in dialysis patients with hypertension admitted to intensive care unit

  2025influential citation
• Should We Use Renin–Angiotensin-System Inhibitors As a First-Line Therapy for the Management of Hypertension in Patients Receiving Hemodialysis?

  2025influential citation
• Hypertension and Blood Pressure Control in Hemodialysis Patients

  2025cites this paper
• Comparison between the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and their combination on mortality in maintenance dialysis patients: a systematic review and meta-analysis

  2024cites this paper
• Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management.

  2024cites this paper
• Impact of Angiotensin Receptor Blockers (ARB) versus Other Antihypertensive Medication on Blood Pressure in Patients on Dialysis: A Meta-Analysis

  2024cites this paper
• Protection against Incidences of Serious Cardiovascular Events Study with daily fish oil supplementation in dialysis patients (PISCES): protocol for a randomised controlled trial

  2024cites this paper
• Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study

  2024cites this paper
• Another evidence that supports the continued use of RAS inhibitors in end-stage kidney diseases

  2024cites this paper
• Pathophysiological concepts and screening of cardiovascular disease in dialysis patients

  2023cites this paper
• Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association.

  2023cites this paper
• Hypertension in Patients Receiving Dialysis: A Review of the Current Clinical Approach

  2023cites this paper
• Diagnosis and treatment of hypertension in dialysis patients: a systematic review

  2023cites this paper
• The Controversies of Coronary Artery Disease in End-Stage Kidney Disease Patients: A Narrative Review

  2023cites this paper
• Antihypertensive treatment of end-stage renal disease patients on hemodialysis does not alter circulating ACE and ACE2 activity and angiotensin peptides.

  2023cites this paper
• Effect of renin–angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

  2023cites this paper
• Epidemiology, Pathophysiology, and Clinical Perspectives of Intradialytic Hypertension

  2023cites this paper
• A Case of Significant Improvement of Heart Failure With Reduced Ejection Fraction With a Small Dose of Candesartan in a Hemodialysis Patient With Hypertensive Heart Disease and Nephrosclerosis

  2023cites this paper
• Pharmacological management of hypertension and outcome among patients on hemodialysis at Muhimbili National Hospital, Tanzania: a cross-sectional study

  2023cites this paper
• Overview of research progress on the association of dietary potassium intake with serum potassium and survival in hemodialysis patients, does dietary potassium restriction really benefit hemodialysis patients?

  2023cites this paper
• Management of arterial hypertension in patients with chronic kidney disease on hemodialysis

  2022cites this paper
• Effect of angiotensin converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis.

  2022cites this paper
• Renin-Angiotensin-Aldosterone System (RAS) Inhibitors May Suppress the Prevalence of Peripheral Arterial Disease (PAD) in Elderly, Chronic Hemodialysis Patients

  2022cites this paper
• Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes

  2021cites this paper
• Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis

  2021cites this paper
• Taking a Step Further in Identifying Ideal Blood Pressure Range Among Hemodialysis Patients: A Systematic Review and a Meta-Analysis

  2020cites this paper
• Effects of ACEIs and ARBs on the Residual Renal Function in Peritoneal Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials

  2020cites this paper
• Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  2020cites this paper
• Inflammation in Chronic Kidney Disease

  2020cites this paper
• Antihypertensive therapy in patients receiving maintenance hemodialysis: a narrative review of the available clinical-trial evidence.

  2020cites this paper
• Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• Coronary Artery Disease: Therapeutics and Drug Discovery

  2020cites this paper
• Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis

  2020cites this paper
• Hypertension Drug Therapy.

  2020cites this paper
• Uncertainties in BP management in dialysis patients

  2020cites this paper
• Longer predialysis ACEi/ARB utilization is associated with reduced postdialysis mortality.

  2020cites this paper
• Antihypertensive Agents in the Dialysis Patient

  2019cites this paper
• Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.

  2019cites this paper
• Redefining Medication Management in Dialysis: A Kidney Pharmacy Quality Pyramid

  2019cites this paper
• Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?

  2018cites this paper
• Patient-Centered Approach for Hypertension Management in End-Stage Kidney Disease: Art or Science?

  2018cites this paper
• Blood pressure control in conventional hemodialysis

  2018cites this paper
• Management of Hypertension in Patients with Chronic Kidney Disease and End-stage Renal Disease

  2018cites this paper
• DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.

  2018cites this paper
• Hypertension in Dialysis Patients: Clinical Epidemiology, Pathogenesis, Diagnosis, and Treatment

  2018cites this paper
• Cardioprotective Exercise and Pharmacologic Interventions as Complementary Antidotes to Cardiovascular Disease

  2018cites this paper
• Hypertension in patients on dialysis: diagnosis, mechanisms, and management

  2018cites this paper
• Effect of renin-angiotensin system blockade in patients with severe renal insufficiency and heart failure.

  2018cites this paper
• Syncope and Collapse Are Associated with an Increased Risk of Cardiovascular Disease and Mortality in Patients Undergoing Dialysis

  2018cites this paper
• End‐stage renal disease patients using angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study

  2018cites this paper
• Impact of end stage renal disease on in-hospital outcomes of patients with systolic and diastolic heart failure (insights from the Nationwide Inpatient Sample 2010 to 2014).

  2018cites this paper
• Korean Guidelines for Diagnosis and Management of Chronic Heart Failure

  2017cites this paper
• Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease.

  2017cites this paper
• Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients

  2017cites this paper
• Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.

  2017cites this paper
• Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review

  2017cites this paper
• [Elevated serum aldosterone levels in dialysis patients: Are we underusing renin-angiotensin-aldosterone system blockers?]

  2017cites this paper
• Treatment of Hypertension in Light of the New Guidelines: Pharmacologic Approaches Using Combination Therapies

  2017cites this paper
• RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan

  2017cites this paper
• Cardiovascular Disease in Dialysis Patients

  2017cites this paper
• Efficacy of antihistamines on mortality in patients receiving maintenance hemodialysis: an observational study using propensity score matching

  2017cites this paper
• Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors

  2017cites this paper
• Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain

  2017cites this paper
• Resistant Hypertension in Chronic Kidney Disease

  2017cites this paper
• Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials

  2017cites this paper
• Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis

  2017cites this paper
• Special situations: Intradialytic hypertension/chronic hypertension and intradialytic hypotension

  2017cites this paper
• Sudden Cardiac Death in CKD and ESKD: Risk Factors, Mechanisms, and Therapeutic Strategies

  2017cites this paper
• Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies.

  2016cites this paper
• A systematic review on randomized control trials on rennin angiotensin aldosterone system inhibitors role in managing hypertension among hemodialysis patients

  2016cites this paper
• Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis

  2016cites this paper
• Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis

  2016cites this paper
• Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis

  2016cites this paper
• [Cardiac arrest in dialysis patients: Risk factors, preventive measures and management in 2015].

  2016cites this paper
• Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.

  2016cites this paper
• Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.

  2016cites this paper
• Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis

  2016cites this paper
• Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup

  2016cites this paper
• Management of hypertension for patients undergoing dialysis therapy

  2016cites this paper
• Hypertension in the Dialysis Patient

  2016cites this paper
• Pharmacotherapy of Hypertension in Chronic Dialysis Patients.

  2016cites this paper
• Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis

  2016cites this paper
• Controversies and problems of volume control and hypertension in haemodialysis.

  2016cites this paper
• Effects of Renin‐Angiotensin‐Aldosterone System Blockade in Patients with End‐Stage Renal Disease§, ☆

  2016cites this paper
• Hypertension Management in Transition: From CKD to ESRD.

  2016cites this paper
• Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists

  2016cites this paper
• Management of hypertension in patients with end-stage renal disease leading to haemodialysis: a challenge

  2016cites this paper
• Left Ventricular Diastolic Dysfunction in End‐Stage Kidney Disease: Pathogenesis, Diagnosis, and Treatment

  2015cites this paper
• Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients

  2015cites this paper
• Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease

  2015cites this paper
• Understanding Hypertension in Patients on Hemodialysis.

  2015cites this paper
• Sudden Cardiac Death and Arrhythmia in CKD

  2015cites this paper
• Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)

  2015cites this paper
• Prevention of Heart Failure in Patients with Chronic Kidney Disease

  2015cites this paper
• Antihypertensive Medications in End‐Stage Renal Disease

  2015cites this paper
• ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II – Management of Various Cardiovascular Complications

  2015cites this paper
• Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality?

  2014cites this paper
• Assessment and management of hypertension in patients on dialysis.

  2014cites this paper
• Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis

  2014cites this paper